BIN1 was found to be downregulated in breast cancer, colon cancer, ovarian cancer, clear cell renal cell carcinoma (RCC), uterine corpus endometrial carcinoma (UCEC), lung cancer, glioblastoma, and liver cancer, suggesting its potential role as a key regulator in cancer progression (Fig. 1a). Here, BIN1 is linked to ovarian cancer.